Endothelin receptor blockade improves fluid sequestration, pancreatic capillary blood flow, and survival in severe experimental pancreatitis

Annals of Surgery

Volumn 228, Issue 5, 1998, Pages 670-675

  Foitzik, Thomas ^a   Faulhaber, Jörg ^a   Hotz, Hubert G ^a   Kirchengast, Michael ^b   Buhr, Heinz J ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; TRYPSINOGEN;

ANIMAL MODEL; ARTICLE; CAPILLARY FLOW; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; HEMATOLOGICAL PARAMETERS; MALE; NONHUMAN; PANCREAS BLOOD FLOW; PANCREAS DISEASE; PANCREATITIS; PRIORITY JOURNAL; RAT; URINE VOLUME;

ACUTE DISEASE; ANIMALS; BODY FLUIDS; CAPILLARIES; MALE; PANCREAS; PANCREATITIS, ACUTE NECROTIZING; PHENYLPROPIONATES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0032470695     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199811000-00006     Document Type: Article

References (38)

1. Schmidt J, Fernandez del Castillo C, Rattner DW, Lewandrowski KB, Messmer K, Warshaw AL. Hyperoncotic ultrahigh molecular weight dextran solutions reduce trypsinogen activation, prevent acinar necrosis, and lower mortality in rodent pancreatitis. Am J Surg 1993; 165:40-45.
2. Mithöfer K, Fernandez-del Castillo C, Ferraro MJ, Lewandrowski KB, Rattner DW, Warshaw AL. Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Gastroenterology 1996; 110:232-240.
3. Werner J, Schmidt J, Langer C, Gebhard MM, Herfarth C, Klar E. Superiority of dextran compared to crystalloids and other colloids in the treatment of acute necrotizing pancreatitis [abstract]. Pancreas 1995; 11:452.
4. Foitzik T, Fernandez-del Castillo C, Rattner DW, Ferraro MJ, Warshaw AL. Pathogenesis and prevention of early pancreatic infection in experimental acute necrotizing pancreatitis. Ann Surg 1995; 222:179-185.
5. Klar E, Foitzik T, Buhr HJ, Messmer K, Herfarth C. Isovolemic hemodilution with dextran 60 as treatment of pancreatic ischemia in acute pancreatitis. Ann Surg 1993; 217:369-374.
6. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176:480-483.
7. Luiten EJT, Hop WCJ, Lange JF, Briuning HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995; 222:57-65.
8. McMillen MA, Sumpio BE. Endothelins: polyfunctional cytokines. J Am Coll Surg 1995; 180:621-637.
9. Epstein FH. Mechanism of disease. N Engl J Med 1995; 10:356-363.
10. Mandavilli U, Schmid J, Rattner DW, Watson WT, Warshaw AL. Continuous complete collection of uncontaminated urine in conscious rodents. Laboratory Animal Science 1991; 41:258-261.
11. Schmidt J, Rattner DW, Lewandrowski K, et al. A better model of acute pancreatitis for evaluating therapy. Ann Surg 1992; 215:44-56.
12. Mithöfer K, Schmidt J, Gebhard MM, Buhr HJ, Herfarth C, Klar E. Measurement of blood flow in pancreatic exchange capillaries with FITC-labelled erythrocytes. Microvasc Res 1995; 49:33-48.
13. Hotz HG, Schmidt J, Ryschich EW, et al. Isovolemic hemodilution with dextran prevents contrast medium-induced impairment of pancreatic microcirculation in necrotizing pancreatitis in the rat. Am J Surg 1995; 169:161-166.
14. Hurley PR, Cook A, Jehanli A, et al. Development of radioimmunoassays for free tetra-1-aspartyl-L-lysine-trypsinogen activation peptides (TAP). J Immunol Methods 1988; 111:195-203.
15. Mann DV, Hershman MJ, Hittinger R, Glazer G. Multicentre audit of death from acute pancreatitis. Br J Surg 1994; 81:890-893.
16. De Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KCH. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 83:349-353.
17. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
18. Takaori K, Inoue K, Kogire M, et al. Effects of endothelin on microcirculation of the pancreas. Life Sci 1992; 51:615-622.
19. Liu XH, Kimura T, Ishikawa H, et al. Effect of endothelin-1 on the development of hemorrhagic pancreatitis in rats. Scand J Gastroenterol 1995; 30:276-282.
20. Arai H, Hori S, Aramori I, Ohkubo H, Nakanashi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London) 1990; 348:730-732.
21. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (London) 1990; 348:732-735.
22. Knoll: Investigator's brochure, LU 135252, 2d ed. Ludwigshafen, 1997:14-32.
23. Riechers H, Albrecht H-P, Amberg W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 1996; 39:2123-2128.
24. Mu̧nter K, Hergenröder S, Unger L, Kirchengast M. Oral treatment with an ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett 1996; 2:90-92.
25. Raschack M, Unger L, Riechers H, Klinge D. Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 1995; 26 (Suppl 3):S397-S399.
26. D'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Lu̧scher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997; 29:435-441.
27. Birck R, Knoll T, Kränzlin B, et al. Improvement of acute renal failure in rats with oral endothelin receptor antagonist LU 135252 [abstract]. J Am Soc Nephrol 1996; 7:A2876.
28. Kogire M, Inoue K, Higashide SI, et al. Protective effects of endothelin-1 on acute pancreatitis in rats. Digest Dis Sci 1995; 40:1207-1212.
29. Foitzik T, Bassi DG, Schmidt J, et al. Intravenous contrast medium accentuates the seventy of acute necrotizing pancreatitis in the rat. Gastroenterology 1994; 106:207-214.
30. Foitzik T, Faulhaber J, Hotz HG, Kirchengast M, Buhr HJ. Endothelin-1 triggert die Ausbildung der schweren akuten Pankreatitis. Langenbecks Arch 1997(Suppl 1); 749-753.
31. Banks PA, Tenner S, Noordhoek EC, Sica G, Feng S, Zinner M. Does pancreatic necrosis predict severity in patients with acute pancreatitis? [abstract]. Digestion 1996; 57:218.
32. Weidenbach H, Lerch MM, Gress TM, Pfaff D, Turi S, Adler G. Vasoactive mediators and the progression from edematous to necrotizing experimental acute pancreatitis. Gut 1995; 37:434-440.
33. Yotsumoto F, Manabe T, Ohshio G, et al. Role of pancreatic blood flow and vasoactive substances in the development of canine acute pancreatitis. J Surg Res 1993; 55:531-536.
34. Kirkpatrick CJ, Bittinger F, Klein CL, Hauptmann S, Klosterhalfen B. The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective. Virchows Arch 1996; 427:461-476.
35. Gullo A, Berlot G. Ingredients of organ dysfunction or failure. World J Surg 1996; 20:430-436.
36. Hotz HG, Foitzik T, Rohweder J, et al. Intestinal microcirculation and gut permeability in acute pancreatitis. Early changes and therapeutic implications, J Gastrointest Surg (in press).
37. 1 on acute lung injury of caerulein-induced acute pancreatitis in rats. Am J Physiol 1997; 272(1.1):G23-30.
38. Lewis MPN, Kusske AM, Todd KE, Toyama MT, Ashley SW, Reber HA. An endothelin ETa/ETb receptor antagonist improves the severity of experimental pancreatitis in rats. Surg Forum 1996; 47:135-137.